$ARVN in 29.35 Cypher Looking for 32+ (tp1) 1.2% risk, stop below X
May add with price action will share if I do
−5.53USD
−282.5MUSD
131.4MUSD
47.308M
About Arvinas, Inc.
Sector
Industry
CEO
John G. Houston
Website
Headquarters
New Haven
Employees (FY)
415
Founded
2013
ISIN
US04335A1051
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Buy ARVN 8/9/2021Stock above EXMA 200 and still in uptrend
Stock is making higher low
EXMA 13 is equal EXMA 34
So you can buy target 105.3 stop loss 81.98
Good luck
ARVINAS STOCK PRICE SHOWING SOME STRENGTHOne of the stocks that came on my scan this week is ARVN. Gapped-Up December 2020 and has since pullback to value zone. Technically, looking prepared to move up again to re-test its January Swing High, however, another earning report is due 17 days time (Earnings may be dynamic and has nothing to do
Arvinas Nearly Doubles on Promising Cancer Drug ResultsArvinas Nearly Doubles on Promising Cancer Drug Results
The test results show the Arvinas drugs' potential for treating breast and prostate cancer, Cantor said.
Arvinas (ARVN) - Get Report shares blasted off Monday as Cantor Fitzgerald offered bullish comments on the biopharmaceutical company aft
ARVINAS INCAfter breaking the level of (36) with power . the market did a little pullback. but he was weak. at the moment there is a big probability that he will go around (20)
ARVN Short, purely speculative based on chartShort, purely speculative based on chart.
Seems to have a nice run to 2.816 Fib. that is plenty on couple of months. Target $28
Arvinas Pharmaceuticals likely to reach 25.60Arvinas Pharmaceuticals is on a run thanks to FDA approval of phase 1 clinical trials on a new drug. It's above critical resistance levels and appears to have clearance up to 25.60.
Personally I won't be taking a position in this one, though. Arvinas's earnings are pretty garbage, and honestly a ph
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
